Article
Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
Cell biology international - 1 Feb 2019
Zhang Tieqiong, Zheng Chunlei, Hou Kezuo, Wang Jinyao, Zhang Ye, Fan Yibo, Zhao Huan, Qu Xiujuan, Liu Yunpeng, Kang Jian, Che Xiaofang, Hu Xuejun
Abstract excerpt
Although epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) could greatly improve the prognosis of NSCLC patients harboring activating EGFR mutations, drug resistance still remains a major obstacle to successful treatment. Our previous study found that the EGFR-TKI icotinib could upregulate the expression of Casitas-B-lineage lymphoma protein-B (Cbl-b), an E3 ubiquitin ligase. In the present...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.